Tivic Health Systems Inc

Discover how Tivic Health’s 2025 pivot to TLR5‑based Entolimod & Entolasta boosts immunotherapy prospects, scale‑up production, and government partnership plans.

Investors weigh Tivic Health’s clinical promise against its stark losses—GAAP EPS –$1.97, $150k revenue, yet breakthrough nerve‑stimulation trials spark debate.

Tivic Health Systems, Inc. has made strategic moves to advance its microcurrent therapy solutions for chronic diseases, including a manufacturing agreement and new patent related to vagus nerve stimulation technology.